Dexasone LA injection and Lefamulin Injection
Determining the interaction of Dexasone LA injection and Lefamulin Injection and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.GENERALLY AVOID: Coadministration with potent or moderate inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may significantly decrease the plasma concentrations of lefamulin, which is a substrate of both the isoenzyme and efflux transporter. When oral lefamulin was administered with oral rifampin, a potent CYP450 3A4/P-gp inducer, mean lefamulin peak plasma concentration (Cmax) and systemic exposure (AUC) decreased by 57% and 72%, respectively. Coadministration of intravenous lefamulin with oral rifampin reduced mean lefamulin Cmax and AUC by 8% and 28%, respectively. Reduced therapeutic efficacy may occur. MANAGEMENT: Concomitant use of lefamulin with potent or moderate inducers of CYP450 3A4 and/or P-gp should be avoided unless the benefit outweighs the risks. Monitor for reduced efficacy of lefamulin if coadministration is necessary. References "Product Information. Xenleta (lefamulin)." Nabriva Therapeutics US, Inc., King of Prussia, PA.
Professional:GENERALLY AVOID: Coadministration with potent or moderate inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may significantly decrease the plasma concentrations of lefamulin, which is a substrate of both the isoenzyme and efflux transporter. When oral lefamulin was administered with oral rifampin, a potent CYP450 3A4/P-gp inducer, mean lefamulin peak plasma concentration (Cmax) and systemic exposure (AUC) decreased by 57% and 72%, respectively. Coadministration of intravenous lefamulin with oral rifampin reduced mean lefamulin Cmax and AUC by 8% and 28%, respectively. Reduced therapeutic efficacy may occur.
MANAGEMENT: Concomitant use of lefamulin with potent or moderate inducers of CYP450 3A4 and/or P-gp should be avoided unless the benefit outweighs the risks. Monitor for reduced efficacy of lefamulin if coadministration is necessary.
- "Product Information. Xenleta (lefamulin)." Nabriva Therapeutics US, Inc., King of Prussia, PA.
Generic Name: dexamethasone
Brand name: De-Sone LA, Dexacen-4, Dexasone, Dexasone LA, Solurex, Solurex LA, Baycadron, Dexamethasone Intensol, DexPak 10 Day Taperpak, DexPak 13 DayTaperpak, DexPak 6 DayTaperpak, Decadron, DexPak, TaperDex, Zema-Pak, ZoDex, Zonacort
Synonyms: Dexasone LA (injection)
Generic Name: lefamulin
Brand name: Xenleta
Synonyms: Lefamulin, Lefamulin (oral/injection)
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Dexasone LA injection-Lefamulin Tablets
- Dexasone LA injection-Leflunomide
- Dexasone LA injection-Legatrin PM
- Dexasone LA injection-Lemtrada
- Dexasone LA injection-Lenalidomide
- Dexasone LA injection-Lenvatinib
- Lefamulin Injection-Dexbrompheniramine
- Lefamulin Injection-Dexbrompheniramine and Acetaminophen Caplets
- Lefamulin Injection-Dexbrompheniramine and phenylephrine
- Lefamulin Injection-Dexbrompheniramine and Phenylephrine Syrup
- Lefamulin Injection-Dexbrompheniramine and Phenylephrine Tablets
- Lefamulin Injection-Dexbrompheniramine and pseudoephedrine